Stavroulopoulos A, Aresti V, Papadopoulos C, Nennes P, Metaxaki P, Galinas A. Bicarbonate levels in hemodialysis patients switching from lanthanum carbonate to sucroferric oxyhydroxide. World J Nephrol 2018; 7(6): 123-128 [PMID: 30324087 DOI: 10.5527/wjn.v7.i6.123]
Corresponding Author of This Article
Aristeidis Stavroulopoulos, BM BCh, MD, Chief Doctor, Doctor, Department of Nephrology, IASIO Hospital, General Clinic of Kallithea, Sivitanidou 36, Athens 17676, Greece. stavoulopoulos@yahoo.co.uk
Research Domain of This Article
Urology & Nephrology
Article-Type of This Article
Observational Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Aristeidis Stavroulopoulos, Vasiliki Aresti, Christoforos Papadopoulos, Panagiotis Nennes, Polixeni Metaxaki, Anastasios Galinas, Department of Nephrology, IASIO Hospital, General Clinic of Kallithea, Athens 17676, Greece
Author contributions: All of the authors contributed to the study design; Stavroulopoulos A, Aresti V and Papadopoulos C collected the data; Stavroulopoulos A analyzed the data and drafted the manuscript; all authors contributed to the conception of the paper, interpretation of data, and subsequent revisions of the manuscript.
Institutional review board statement: The protocol for the research project has been approved by the IASIO Hospital’s Ethics Committee and conforms to the provisions of the Declaration of Helsinki.
Informed consent statement: Informed written consent was obtained from all patients before they entered the study.
Conflict-of-interest statement: None to declare.
STROBE statement: The authors have read the STROBE Statement-checklist of items, and the manuscript was prepared and revised according to the STROBE Statement-checklist of items.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Aristeidis Stavroulopoulos, BM BCh, MD, Chief Doctor, Doctor, Department of Nephrology, IASIO Hospital, General Clinic of Kallithea, Sivitanidou 36, Athens 17676, Greece. stavoulopoulos@yahoo.co.uk
Telephone: +30-69-47824197 Fax: +30-21-09583722
Received: June 4, 2018 Peer-review started: June 4, 2018 First decision: July 11, 2018 Revised: August 2, 2018 Accepted: August 30, 2018 Article in press: August 30, 2018 Published online: October 10, 2018 Processing time: 128 Days and 13.1 Hours
ARTICLE HIGHLIGHTS
Research background
The effect of phosphate binders in clinically important outcomes, such as metabolic acidosis, remains understudied.
Research motivation
There are no studies examining the effect of the novel phosphate binder sucroferric oxyhydroxide (SFOH) on acid-base status.
Research objectives
Examine possible alterations in acid-base parameters in hemodialysis patients switching from lanthanum carbonate (LanC) to SFOH.
Research methods
Fifteen stable hemodialysis patients switched from LanC to SFOH. We compared pre- and post-switching blood gas analyses, whilst hemodialysis conditions and medications remained stable.
Research results
Switching from LanC to the novel phosphate binder SFOH did not have any significant effect on blood bicarbonate levels and gas analysis. No correlations were found, either between pre-switching LanC daily dose or between post-switching daily dose of the new binder and the measured parameters.
Research conclusions
This is the first study that evaluates acid-base status in patients switching from LanC to the new phosphate binder SFOH, showing that there is no need to change hemodialysis prescription regarding these parameters.
Research perspectives
Our study can serve as a pilot for further studies with a larger number of patients, different binders and extended durations, to better understand their effect in clinically important outcomes, such as metabolic acidosis.
